Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

00:00

The Eyes of Pelobresso

The stock today is 27. At the current price, more than half of that value would be covered by the net cash at the end of this year. So you're paying for less than $13 per share net, you're getting Pelobresso which I think you guys think risk adjusted could be worth as much as $45 per share. We are active engagement in lifetimes. That's the exposure we give to our investors. And when we sat down with John Paul, who's the CEO here, we went through section A, section B, and we came to section C,. The reason why we thought they'd underperformed was obviously, we thought that Majouvi was potentially

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app